risks with glp 1 The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action GLP-1 Medications Infographic | Medidex
Description
There isn't a lot of information on cagrilintide monotherapy yet
While these groups may not have medical professional support, they can provide valuable peer connection and motivation
In the UK, clinicians and patients can report suspected adverse drug reactions via the MHRA Yellow Card scheme (online/app/clinical systems)
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: A meta-analysis
And its important to remember that not everyone reaches or tolerates the maximum dose
PIONEER 10 Investigators
